299 related articles for article (PubMed ID: 30635917)
1. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
[TBL] [Abstract][Full Text] [Related]
2. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
3. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.
Xiong X; Wang X; Lu Y; Wang E; Zhang Z; Yang J; Zhang H; Li X
J Hepatol; 2014 Apr; 60(4):847-54. PubMed ID: 24333182
[TBL] [Abstract][Full Text] [Related]
4. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
[TBL] [Abstract][Full Text] [Related]
5. [Effects of celastrol on autophagy and endoplasmic reticulum stress-mediated apoptosis in a mouse model of nonalcoholic fatty liver disease].
Tian T; Liao XC; Zhang M; Wu XM; Guo YT; Tan SY
Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):656-662. PubMed ID: 36038329
[No Abstract] [Full Text] [Related]
6. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
[TBL] [Abstract][Full Text] [Related]
8. Betulinic acid improves nonalcoholic fatty liver disease through YY1/FAS signaling pathway.
Mu Q; Wang H; Tong L; Fang Q; Xiang M; Han L; Jin L; Yang J; Qian Z; Ning G; Zhang Y; Zhang Z
FASEB J; 2020 Sep; 34(9):13033-13048. PubMed ID: 32777136
[TBL] [Abstract][Full Text] [Related]
9. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
[TBL] [Abstract][Full Text] [Related]
10. Hugan Qingzhi tablets attenuates endoplasmic reticulum stress in nonalcoholic fatty liver disease rats by regulating PERK and ATF6 pathways.
Yang M; Yao X; Xia F; Xiang S; Tang W; Zhou B
BMC Complement Med Ther; 2024 Jan; 24(1):36. PubMed ID: 38216941
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
Zhang C; Liu Y; Wang Y; Ge X; Jiao T; Yin J; Wang K; Li C; Guo S; Xie X; Xie C; Nan F
J Med Chem; 2022 Oct; 65(19):13452-13472. PubMed ID: 36107013
[TBL] [Abstract][Full Text] [Related]
12. FXR controls CHOP expression in steatohepatitis.
Fuchs CD; Claudel T; Scharnagl H; Stojakovic T; Trauner M
FEBS Lett; 2017 Oct; 591(20):3360-3368. PubMed ID: 28895119
[TBL] [Abstract][Full Text] [Related]
13. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
Gai Z; Gui T; Hiller C; Kullak-Ublick GA
J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
[TBL] [Abstract][Full Text] [Related]
15. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
16. iPla2β Deficiency Suppresses Hepatic ER UPR, Fxr, and Phospholipids in Mice Fed with MCD Diet, Resulting in Exacerbated Hepatic Bile Acids and Biliary Cell Proliferation.
Ming Y; Zhu X; Tuma-Kellner S; Ganzha A; Liebisch G; Gan-Schreier H; Chamulitrat W
Cells; 2019 Aug; 8(8):. PubMed ID: 31409057
[No Abstract] [Full Text] [Related]
17. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation.
Yoo J; Cho IJ; Jeong IK; Ahn KJ; Chung HY; Hwang YC
Toxicol Appl Pharmacol; 2018 Dec; 360():18-29. PubMed ID: 30253173
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
20. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway.
Quan HY; Kim DY; Kim SJ; Jo HK; Kim GW; Chung SH
Biochem Pharmacol; 2013 May; 85(9):1330-40. PubMed ID: 23435355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
